BRAVO - Betrixaban Registry Using Real Time Observations in Acute Medical Illness to Assess Venous Thrombosis and Bleeding Outcomes
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Betrixaban (Primary)
 - Indications Venous thromboembolism
 - Focus Therapeutic Use
 - Acronyms BRAVO
 - Sponsors Portola Pharmaceuticals
 
Most Recent Events
- 08 Jun 2020 Status changed from suspended to withdrawn prior to enrolment.
 - 29 Nov 2018 Status changed from not yet recruiting to suspended.
 - 20 Sep 2018 Planned initiation date changed from 1 Aug 2018 to 1 Sep 2018.